SANJEEVI CARANI GROUP
The group focuses its research on Autoimmune diabetes, which include Type 1 Diabetes, LADA and other forms of Diabetes with autoimmune basis, eg Malnutrition Modulated Diabetes Mellitus. Autoimmune Diabetes has a strong genetic basis (its incidence in Sweden is one of the highest in the world). The group’s main interest lies in the understanding of the biomarkers, immunogenetic factors, especially its structural and functional aspects of the MHC genes, in the understanding of the etiology of the disease and finding ways to predict the disease and possibly to prevent the disease.
We have identified several peptides from peptide elution studies that have binding characteristics to T1D associated MHC genes, DR3, DR4, DQ2, DQ8 and DQ6 (0602). The molecular modeling studies have identified the side chain characteristics if the peptides derived from GAD-65, Insulin that fit into the groove of the susceptible and protective HLA associated with T1D.
We have also identified peptides from peptide microarray studies that come from Immune mediators and cell death proteins to which antibodies are identified in T1D patients and not in controls. We are evaluating whether these peptides identify patients with T1D much before they develop disease from DiPiS cohort. A muiltiplex assay is under development using these peptides to use as a screening assay for the detection and prediction of T1D in newborn cohorts.
The group is also pursuing genetic studies in largest collection of T1D families for the maternal-fetal interaction while the fetus is still in the womb. We are testing the hypothesis that autoimmunity in the newborn develops much before the baby is born.
Clinical course in diabetes
Dr. Sanjeevi organizes Clinical Diabetes Course for Karolinska Institutet Medical students who have finished Term-6 of their medical program. It is a 7.5 point program in the core curriculum and the program runs for 5 weeks of which 4 weeks are spent in India (where the students get clinical exposure to Diabetes) and a 1 week is spent at Karolinska Institutet. This program has been running successfully for more than 10 years and is conducted twice a year.
Carani B Sanjeevi, MD, PhD – Associate Professor/Docent.
Dr. Sanjeevi obtained his MD from the University of Madras in India and his Masters in Immunology from Imperial College, London and PhD in Experimental Immunology & Diabetes at Karolinska Institutet (1994).
Dr. Sanjeevi has served as a member of the Editorial board of HUMAN IMMUNOLOGY, member of the International Advisory Board of the Journal of Association of Physicians of India (JAPI) from January 2005, Associate editor for DIABETOLOGIA (published by EASD), member of the Editorial Board of 'Current Diabetes Reviews' from USA and Editor for the 'IMMUNOLOGY OF DIABETES' series published by the Annals of the New York Academy of Sciences (USA). Five volumes had been published.
Dr. Carani Sanjeevi won ‘Pravasi Bharathiya Samman Award’, which is the Highest Award for Person of Indian Origin from Govt of India. Dr. Sanjeevi received the award from the President of India on the evening of January 9, 2017 in Bangalore on the concluding day of the Pravasi Bharathiya Diwas Conference. The Pravasi Bharatiya Samman Award (PBSA) is the highest honour conferred on overseas Indians or Person of Indian origin by the Government of India in recognition of their achievements both in India and abroad. The Award has been given to Dr. Sanjeevi for, 'Eminence in one’s field or outstanding work, which has enhanced India’s prestige in the country of residence'. The award includes a certificate and a gold medal.
Maziarz M, Hagopian W, Palmer JP, Sanjeevi CB, Kockum I, Breslow N, Lernmark Å; Swedish Childhood Diabetes Register; Diabetes Incidence in Sweden Study Group; Type 1 Diabetes Genetics Consortium. Non-HLA type 1 diabetes genes modulate disease risk together with HLA-DQ and islet autoantibodies. Genes Immun. 2015 Dec;16(8):541-51.
Sun C, Sanjeevi S, Luo F, Zhi D, Sanjeevi CB. Interactions between maternal killer cell immunoglobulin receptor genes and foetal HLA ligand genes contribute to type 1 diabetes susceptibility in Han Chinese. Int J Immunogenet. 2016 Jun;43(3):125-30.
Sanjeevi S, Sun C, Kanungo A, Sanjeevi CB. Killer immunoglobulin receptor genes and their HLA-C ligand are associated with Type 1 diabetes in an Eastern Indian population. Diabet Med. 2016 Jan;33(1):91-6.
Onengut-Gumuscu S, Chen WM, Burren O, Cooper NJ, Quinlan AR, Mychaleckyj JC, Farber E, Bonnie JK, Szpak M, Schofield E, Achuthan P, Guo H, Fortune MD, Stevens H, Walker NM, Ward LD, Kundaje A, Kellis M, Daly MJ, Barrett JC, Cooper JD, Deloukas P; Type 1 Diabetes Genetics Consortium, Todd JA, Wallace C, Concannon P, Rich SS. Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers. Nat Genet. 2015 Apr;47(4):381-6.
Sun C, Zhi D, Shen S, Luo F, Sanjeevi CB. SNPs in the exons of Toll-like receptors are associated with susceptibility to type 1 diabetes in Chinese population. Hum Immunol. 2014 Nov;75(11):1084-8.
Sun C, Sedimbi SK, Ashok AK, Sanjeevi CB; Swedish Childhood Diabetes and the Diabetes Incidence in Sweden Study Groups. CRYAB-650 C>G (rs2234702) affects susceptibility to Type 1 diabetes and IAA-positivity in Swedish population. Hum Immunol. 2012 Jul;73(7):759-66.
Sanjeevi CB. Autoimmune diseases and risk of pulmonary embolism. Lancet. 2012 Jan 21;379(9812):200-1. No abstract available.
Hunt KA, et al. Rare and functional SIAE variants are not associated with autoimmune disease risk in up to 66,924 individuals of European ancestry.
Nat Genet. 2011 Dec 27;44(1):3-5. No abstract available.